Macquarie Group
MRSN

Macquarie Group’s Mersana Therapeutics MRSN Stock Holding History

Macquarie Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,000
Closed -$44K – 1661
2025
Q2 		$44K Hold
6,000
– – ﹤0.01% 1591
2025
Q1 		$52K Hold
6,000
– – ﹤0.01% 1567
2024
Q4 		$215K Hold
6,000
– – ﹤0.01% 1510
2024
Q3 		$284K Hold
6,000
– – ﹤0.01% 1529
2024
Q2 		$302K Hold
6,000
– – ﹤0.01% 1525
2024
Q1 		$672K Hold
6,000
– – ﹤0.01% 1419
2023
Q4 		$348K Hold
6,000
– – ﹤0.01% 1507
2023
Q3 		$191K Hold
6,000
– – ﹤0.01% 1531
2023
Q2 		$494K Hold
6,000
– – ﹤0.01% 1459
2023
Q1 		$617K Hold
6,000
– – ﹤0.01% 1440
2022
Q4 		$879K Sell
6,000
-152
-2% -$25.7K ﹤0.01% 1444
2022
Q3 		$1.04M Sell
6,152
-25
-0.4% -$4.06K ﹤0.01% 1412
2022
Q2 		$713K Hold
6,177
– – ﹤0.01% 1547
2022
Q1 		$617K Hold
6,177
– – ﹤0.01% 1623
2021
Q4 		$960K Sell
6,177
-94
-1% -$18.3K ﹤0.01% 1564
2021
Q3 		$1.48M Buy
6,271
+211
+3% +$61.6K ﹤0.01% 1476
2021
Q2 		$2.06M Hold
6,060
– – ﹤0.01% 1411
2021
Q1 		$2.45M Sell
6,060
-18
-0.3% -$8.73K ﹤0.01% 1132
2020
Q4 		$4.04M Hold
6,078
– – 0.01% 922
2020
Q3 		$2.83M Hold
6,078
– – ﹤0.01% 949
2020
Q2 		$3.56M Buy
+6,078
New +$2.08M 0.01% 869

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Macquarie Group's MRSN Position: Q3 2025 in Review

Macquarie Group sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 6,000 shares — an estimated $44K sold.

Macquarie Group first reported a position in MRSN in Q2 2020 and held it in 21 quarters. The position peaked at $4.04M in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Macquarie Group reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Macquarie Group sold 6,000 Mersana Therapeutics shares in Q3 2025, an estimated $44K.
  • Macquarie Group first reported a position in Mersana Therapeutics in Q2 2020 and held it in 21 quarters.
  • Macquarie Group's Mersana Therapeutics position peaked at $4.04M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Macquarie Group's 13F filing for Q3 2025, filed 13 Nov 2025.